Research progress of anti-tumor antibodies
10.3760/cma.j.issn.1006-9801.2015.08.021
- VernacularTitle:抗肿瘤抗体药物的研究进展
- Author:
Ying JIN
- Publication Type:Journal Article
- Keywords:
Neoplasms;
Antibodies,monoclonal
- From:
Cancer Research and Clinic
2015;27(8):572-576
- CountryChina
- Language:Chinese
-
Abstract:
The progress of anti-tumor antibodies can be summarized as three stages:naked antibody,monoclonal antibody,and gene engineering antibody.In 1997,for the first time,a monoclonal antibody——the chimeric anti-CD20 molecule rituximab,was approved by the US FDA for treatment of cancer patients.Since then,monoclonal antibodies have experienced rapid development and have been the main strategy to treat the tumor in the past decade.This article reviewed the clinical application and current state of monoclonal antibody for targeted-tumor therapy.
